Delving into the Latest Updates on Shanghai Bozhiyanxin Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Digestive System Disorders

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	8
Infectious Diseases	6
Immune System Diseases	3
Neoplasms	2
Endocrinology and Metabolic Disease	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Chemical drugs	15
Small molecule drug	13
Unknown	5

Top 5 Target	Count

5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor	1
SCNA(Sodium voltage-gated channel alpha subunits)	1
Sodium channels	1
SV2A(Synaptic vesicle glycoprotein 2A)	1
HIF-PHs(Hypoxia-inducible factor prolyl hydroxylase)	1

Primary objective: To evaluate the efficacy of daprestat in treating renal anemia in non-dialysis chronic kidney disease (CKD) participants, using human erythropoietin injection as a control. Secondary objective: To evaluate the safety of daprestat in treating renal anemia in non-dialysis CKD participants, using human erythropoietin injection as a control.

Start Date22 Aug 2026

Sponsor / Collaborator

Shanghai Bozhiyan New Drug Research Co., Ltd.

CTR20254383

/ RecruitingPhase 3

比较达普司他片和达依泊汀α注射液治疗维持性血液透析慢性肾脏病患者肾性贫血的有效性和安全性的Ⅲ期临床研究

[Translation] A Phase III clinical trial comparing the efficacy and safety of dapoxetine tablets and dapoxetine alpha injection in the treatment of renal anemia in patients with chronic kidney disease undergoing maintenance hemodialysis.

主要目的：以达依泊汀α注射液为对照，评估达普司他片治疗维持性血液透析慢性肾脏病（CKD）参与者肾性贫血的有效性。次要目的：以达依泊汀α注射液为对照，评估达普司他片治疗维持性血液透析CKD参与者肾性贫血的安全性

[Translation]

Primary objective: To evaluate the efficacy of daprestat tablets in treating renal anemia in maintenance hemodialysis participants with chronic kidney disease (CKD), using daprestat alpha injection as a control. Secondary objective: To evaluate the safety of daprestat tablets in treating renal anemia in maintenance hemodialysis participants with CKD, using daprestat alpha injection as a control.

Start Date02 Aug 2026

Sponsor / Collaborator

Shanghai Bozhiyan New Drug Research Co., Ltd.

CTR20260019

/ CompletedPhase 1

BCM476胶囊与盐酸奈必洛尔片及苯磺酸氨氯地平片的药代动力学比较研究

[Translation] Comparative pharmacokinetic study of BCM476 capsules with nebivolol hydrochloride tablets and amlodipine besylate tablets

主要目的观察BCM476胶囊在中国健康受试者中单次口服给药后体内动力学过程，估算相应的药代动力学参数，并以盐酸奈必洛尔片（NEBILETTM）和苯磺酸氨氯地平片（络活喜®），进行药代动力学比较研究，以确定本品中的活性成份不存在药代动力学相互作用。次要研究目的观察BCM476胶囊受试制剂（T）和对照制剂（R1）盐酸奈必洛尔片以及对照制剂（R2）苯磺酸氨氯地平片在中国健康人体中的安全性。

[Translation]

Primary Objective: To observe the pharmacokinetic process of BCM476 capsules in healthy Chinese subjects after a single oral administration, estimate the corresponding pharmacokinetic parameters, and conduct a pharmacokinetic comparison study with nebivolol hydrochloride tablets (NEBILET™) and amlodipine besylate tablets (Norvasc®) to determine that there are no pharmacokinetic interactions between the active ingredients in this product. Secondary Objective: To observe the safety of the test formulation (T) and control formulations (R1) nebivolol hydrochloride tablets and (R2) amlodipine besylate tablets in healthy Chinese subjects.

Start Date23 Dec 2025

Sponsor / Collaborator

Shanghai Bozhiyanxin Pharmaceutical Co., Ltd.

100 Clinical Results associated with Shanghai Bozhiyanxin Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Bozhiyanxin Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Bozhiyanxin Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Bozhiyanxin Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Oct 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

13

Preclinical

IND Application

4

11

IND Approval

Phase 1

5

1

Phase 3

NDA/BLA

4

1

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BCM335	Lung Cancer More	NDA/BLA
Daprodustat ( HIF-PHs )	Anemia in chronic kidney disease More	Phase 3
Ibuprofen ( CAIX x COX-1 x COX-2 )	Migraine Disorders More	Phase 1
BCM-894	Duodenal Ulcer More	Phase 1
BCM863	Essential Hypertension More	Phase 1